These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29417461)

  • 1. Individualizing PSA Monitoring Among Older Prostate Cancer Survivors.
    Shi Y; Fung KZ; John Boscardin W; Ngo S; Freedland SJ; Wong ML; Walter LC
    J Gen Intern Med; 2018 May; 33(5):602-604. PubMed ID: 29417461
    [No Abstract]   [Full Text] [Related]  

  • 2. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: measuring PSA.
    Pezaro C; Woo HH; Davis ID
    Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection rate of prostate cancer following biopsy among the northern Han Chinese population: a single-center retrospective study of 1022 cases.
    Jia Y; Zhu LY; Xian YX; Sun XQ; Gao JG; Zhang XH; Hou SC; Zhang CC; Liu ZX
    World J Surg Oncol; 2017 Aug; 15(1):165. PubMed ID: 28851376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performed.
    Carter HB
    Oncology (Williston Park); 2014 Feb; 28(2):155-6. PubMed ID: 24701706
    [No Abstract]   [Full Text] [Related]  

  • 7. [What does "PSA recurrence mean? "Active surveillance" for all risk groups is an option].
    Hautmann R
    Urologe A; 2006 Oct; 45(10):1239. PubMed ID: 17006696
    [No Abstract]   [Full Text] [Related]  

  • 8. Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?
    Prasad V
    Med Hypotheses; 2016 Aug; 93():71-3. PubMed ID: 27372859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.
    Tikkinen KAO; Dahm P; Lytvyn L; Heen AF; Vernooij RWM; Siemieniuk RAC; Wheeler R; Vaughan B; Fobuzi AC; Blanker MH; Junod N; Sommer J; Stirnemann J; Yoshimura M; Auer R; MacDonald H; Guyatt G; Vandvik PO; Agoritsas T
    BMJ; 2018 Sep; 362():k3581. PubMed ID: 30185545
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis.
    Shen MJ; Nelson CJ; Peters E; Slovin SF; Hall SJ; Hall M; Herrera PC; Leventhal EA; Leventhal H; Diefenbach MA
    Med Decis Making; 2015 May; 35(4):477-86. PubMed ID: 25385751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish Prostate Cancer Screening Trial.
    Schaeffer EM
    J Urol; 2014 Jun; 191(6):1808. PubMed ID: 25280286
    [No Abstract]   [Full Text] [Related]  

  • 15. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen.
    Stamey TA; Graves HC; Wehner N; Ferrari M; Freiha FS
    J Urol; 1993 Apr; 149(4):787-92. PubMed ID: 7681119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A continuous fall of PSA use for prostate cancer screening among Brazilian doctors since 2001. Good or bad notice?
    Araújo FAGDR; Sumita NM; Barroso UO
    Int Braz J Urol; 2019; 45(3):478-485. PubMed ID: 31038862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Aging Mountaineer: PSA screening in older men--of value or should we skip this test?
    Crigger C; Salkini M; Zaslau S
    W V Med J; 2016; 112(3):36-40. PubMed ID: 27301153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should you skip your PSA test? The science is uncertain for now, so arm yourself with deep knowledge of the pros and cons of prostate cancer screening.
    Harv Mens Health Watch; 2012 Oct; 17(3):1, 7. PubMed ID: 23175860
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
    Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
    Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen testing and prostate cancer screening.
    Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
    Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.